Severity
Low
FDA Drug recall · Reported September 6, 2023
Defective Container: slow leakage under the cap
Contract Pharmaceuticals Limited Canada recalled Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Rx only, Manufactured by: C… - a low-severity action.
Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Rx only, Manufactured by: C… was recalled by Contract Pharmaceuticals Limited Canada in September 6, 2023. Reason: Defective Container: slow leakage under the cap. Check the official notice for the remedy. Verify recall #D-1139-2023 with the FDA Drug before acting.
The recall
Contract Pharmaceuticals Limited Canada issued this low-severity FDA Drug recall-Defective Container: slow leakage under the cap.
Sourced from official FDA Drug enforcement records. Verify recall #D-1139-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1139-2023) was formally reported on September 6, 2023, with the manufacturer initiating the action on August 23, 2023. It is classified under Low severity (Class III), with a current status of Terminated. Contract Pharmaceuticals Limited Canada is listed as the recalling firm, operating out of Mississauga, N/A. Federal records list the affected scope as 11,350 bottles.
The documented reason for this recall is: Defective Container: slow leakage under the cap Distribution data in the federal record shows the product reached: Nationwide in the USA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
11,350 bottles
Related Recalls
6
0 from same agency
Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Rx only, Manufactured by: Contract Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, NDC# 71428-003-60
Defective Container: slow leakage under the cap
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1139-2023 |
| Date reported | September 6, 2023 |
| Date initiated | August 23, 2023 |
| Recalling firm | Contract Pharmaceuticals Limited Canada |
| Firm location | Mississauga, N/A |
| Affected scope | 11,350 bottles |
| Distribution | Nationwide in the USA. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 6, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.